‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
LifeMine Therapeutics has secured a massive investment from tech giants Bill Gates and Jeff Bezos, despite conflicting reports on the amount raised.
Evidence dossier
Intelligence passport
Coverage timeline
-
Detected: The first matching coverage entered the Archynetys cluster.
-
Latest coverage observed: Most recent article currently attached to this story cluster.
-
Peak measured velocity: The recorded velocity reached 4.
-
Evidence threshold reached: The story had enough independent coverage for an explanatory brief.
-
Outcome review added: Archynetys revisited the signal after coverage cooled.
Editorial verification ledger: audited by Archynetys Intelligence Desk under our editorial & verification standards.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
- Velocity & Diffusion: 6 dispatches tracked across 6 distinct outlets at live velocity 4.
- Core Signal: LifeMine Therapeutics has secured a massive investment from tech giants Bill Gates and Jeff Bezos, despite conflicting reports on the amount raised.
- Forecast: Archynetys projects coverage will cool within 24 hours.
LifeMine Therapeutics has secured a significant investment from high-profile backers. The biotech firm announced a $188 million funding round. However, other outlets reported a larger figure of $263 million. The discrepancy in reported amounts has sparked interest in the company's prospects.
The investment round includes contributions from funds associated with Bill Gates and Jeff Bezos. LifeMine Therapeutics, led by Greg Verdine, focuses on developing safer immunosuppressants for organ transplants. The company's platform has garnered attention from major investors, indicating strong confidence in its technology and potential. LifeMine Therapeutics aims to revolutionize transplant medicine.
The company's work on safer immunosuppressants could significantly improve outcomes for transplant patients. The backing from Gates and Bezos underscores the potential impact of LifeMine's research. The company's progress and the resolution of the funding discrepancy will be key areas to watch.
Synthesized by Archynetys from verified coverage headlines and grounded web evidence. Updated 105d ago.
Sources (6)
-
Bezos, Gates back LifeMine's transplant aspirations in $263M raiseFirstWord Pharma · 108d ago
-
LifeMine Therapeutics raises $263M; investors include Bezos, Gates fundsThe Business Journals · 108d ago
-
LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investorsmarketscreener.com · 108d ago
-
Greg Verdine’s LifeMine raises $263M for safer immunosuppressantEndpoints News · 108d ago
-
-
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series EFierce Biotech · 108d ago
Questions people are asking
What is LifeMine Therapeutics known for?
LifeMine Therapeutics is known for its work on developing safer immunosuppressants for organ transplants.
Who are the key investors in LifeMine Therapeutics?
Key investors in LifeMine Therapeutics include funds associated with Bill Gates and Jeff Bezos.
What is the reported amount raised by LifeMine Therapeutics?
The reported amount raised by LifeMine Therapeutics varies. One outlet reported $188 million, while others reported $263 million.
Will this story stay in the headlines?
Register your real-time assessment — stored live against this dossier.
Topics
Related trends
Leonardo DiCaprio's Star-Studded Birthday: Jeff Bezos, Orlando Bloom & More Attend
Leonardo DiCaprio marked his 52nd birthday with a high-profile gathering that drew Jeff Bezos, Orlando Bloom, Tobey Maguire, Ice Spice and other boldface names.
Amazon's Astro home robot has fans but looks destined for the 'trash heap.' Why it's trying again
Amazon is building a new home robot team after Astro's limited success, aiming to overcome technical and market challenges.
Servier’s $1.5B bet on Edgewise drug fails five months in
Servier’s $1.6 billion Edgewise trial fails, ending its biggest bet on Becker muscular dystrophy.
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
Ultragenyx slashes costs and reaffirms 2027 profit while Joby Aviation’s earnings lift its stock, spotlighting divergent paths in high‑growth sectors.
Moderna stock jumps on planned national cancer vaccine effort
Moderna stock jumps on planned national cancer vaccine effort
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
Argenx's stock plummets after a surprise failure in a late-stage study of its autoimmune disease drug, but the company is still preparing for a pivotal run with a $2.2B treatment.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
Continue reading in Business
Restaurant Brands International earnings beat as Burger King's U.S. business soars
Burger King's U.S. business is driving Restaurant Brands International's earnings growth, but not all of its brands are faring equally well.
Federal Communications Commission scraps limit on broadcast TV ownership
The FCC's recent decision to scrap limits on broadcast TV ownership is reshaping the media landscape.
Top US Mortgage Lender Plunges Most Ever After Pausing Dividend
The largest mortgage lender in the US has paused its dividend and is seeking a major investment.
Celestica Just Unloaded Bad News
Celestica's $3 billion equity offering has investors worried about the company's valuation and future prospects.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.